Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age

Brazilian Journal of Infectious Diseases

Volumn 18, Issue 1, 2014, Pages 34-41

  Torres, Thiago Silva ^a   Cardoso, Sandra Wagner ^a   Velasque, Luciane S ^a,b   Veloso, Valdilea G ^a   Grinsztejn, Beatriz ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Aging; Antiretroviral; HIV; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE;

ADULT; AGING; ARTICLE; BLOOD TOXICITY; BRAZIL; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RASH; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; YOUNG ADULT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; ANEMIA; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DEMOGRAPHY; GASTROINTESTINAL DISEASE; HAZARD RATIO; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; KIDNEY DISEASE; LIVER DISEASE; LONGITUDINAL STUDY; OBSERVATIONAL STUDY; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; TREATMENT WITHDRAWAL; VIRUS LOAD;

AGING; ANTIRETROVIRAL; HIV; TOXICITY;

ADULT; AGE DISTRIBUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT REFUSAL; VIRAL LOAD; YOUNG ADULT;

EID: 84893681685     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.04.005     Document Type: Article

References (45)

1. Fonseca M.G., Bastos F.I. Twenty-five years of the AIDS epidemic in Brazil: principal epidemiological findings, 1980-2005. Cad Saude Publica 2007, 23(Suppl. 3):S333-S344.
2. Teixeira P.R., Vitória M.A., Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004, 18(Suppl. 3):S5-S7.
3. Althoff K.N., Justice A.C., Gange S.J., et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010, 24:2469-2479.
4. Braithwaite R.S., Kozal M.J., Chang C.C., et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21:1579-1589.
5. Cardoso S.W., Grinsztejn B., Velasque L., et al. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses 2010, 26:865-874.
6. Cesar C., Shepherd B.E., Krolewiecki A.J., et al. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS ONE 2010, 5:e10490.
7. Cicconi P.A., Cozzi-Lepri A., Castagna A., et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med 2010, 11:104-113.
8. d'Arminio Monforte A., Lepri A.C., Rezza G., et al. Italian Cohort of Antiretroviral-naive patients. AIDS 2000, 14:499-507.
9. Dorrucci M., Pezzotti P., Grisorio B., et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001, 15:1733-1736.
10. Hänsel A., Bucher H.C., Nüesch R., Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001, 26:191-193.
11. Hart E., Curtis H., Wilkins E., Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med 2007, 8:186-191.
12. Kumarasamy N., Vallabhaneni S., Cecelia A.J., et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006, 41:53-58.
13. Mocroft A., Phillips A.N., Soriano V., et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:743-752.
14. Mocroft A., Youle M., Moore A., et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001, 15:185-194.
15. Nakimuli-Mpungu E., Nakasujja N., Akena H.D., et al. Effect of older age at initiation of antiretroviral therapy on patients retention in an urban ART program in Uganda. Neurobehav HIV Med 2011, 3:1-8.
16. O'Brien M.E., Clark R.A., Besch C.L., Myers L., Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407-414.
17. van Roon E.N., Verzijl J.M., Juttmann J.R., et al. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:290-294.
18. Vo T.T., Ledergerber B., Keiser O., et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008, 197:1685-1694.
19. Yuan Y., L'Italien G., Mukherjee J., Iloeje U.H. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med Engl 2006, 7:156-162.
20. Carr A., Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009, 23:343-353.
21. Le Moing V., Chêne G., Leport C., et al. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002, 34:239-247.
22. Lodwick R.K., Smith C.J., Youle M., et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008, 22:1039-1046.
23. Staszewski S., Morales-Ramirez J., Tashima K.T., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865-1873.
24. Woldemedhin B., Wabe N.T. The reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in Southern Ethiopia. N Am J Med Sci 2012, 4:19-23.
25. Stone V.E., Jordan J., Tolson J., Miller R., Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004, 36:808-816.
26. Rhee M.S., Greenblatt D.J. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol 2008, 48:1212-1225.
27. Simone M.J., Appelbaum J. HIV in older adults. Geriatrics 2008, 63:6-12.
28. Cordery D.V., Cooper D.A. Optimal antiretroviral therapy for aging. Sex Health 2011, 8:534-540.
29. Grinsztejn B., Veloso V.G., Pilotto J.H., et al. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 2007, 45:515-520.
30. Grinsztejn B., Veloso V.G., Friedman R.K., et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2009, 23:2107-2114.
31. Moreira R.I., Luz P.M., Struchiner C.J., et al. Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr 2011, 57(Suppl. 3):S171-S178.
32. Centers for Disease Control - CDC (USA). Persons aged 50 and older. Available from: [accessed 07.11.12]. http://www.cdc.gov/hiv/topics/over50/index.htm.
33. Lazarus J.V., Nielsen K.K. HIV and people over 50 years old in Europe. HIV Med 2010, 11:479-481.
34. MERCOSUL. Boletim Epidemiológico Intergovernamental de HIV/AIDS da Reunião de Ministros da Saúde do MERCOSUL. Available from: [accessed 07.11.12]. http://www.aids.gov.br/sites/default/files/anexos/publicacao/2012/52038/boletim_epidemiol_gico_do_mercosul_2012_70615.pdf.
35. Ministério da Saúde (Brazil), Secretaria de Vigilância em Saúde, Departamento de DST, AIDS e Hepatites Virais (2011) Boletim Epidemiológico - AIDS e DST. Brasília: Ministério da Saúde: ano VIII, número 1, 2011. Available from: [accessed 07.11.12]. http://www.aids.gov.br/sites/default/files/anexos/publicacao/2011/50652/boletim_aids_2011_final_m_pdf_26659.pdf.
36. Ministério da Saúde (Brazil), Secretaria de Vigilância em Saúde, Departamento de DST, AIDS e Hepatites Virais. Recomendações para Terapia Antirretroviral para Adultos Vivendo com HIV/aids no Brasil. Available from: [accessed 07.11.12]. http://www.aids.gov.br/sites/default/files/anexos/publicacao/2012/52140/consenso_adulto2012_principais_mudancas_pdf_11946.pdf.
37. Antoniou T., Tseng A.L. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002, 36:1598-1613.
38. Knobel H., Guelar A., Valldecillo G., Carmona A., González A., et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 2001, 15:1591-1593.
39. Silverberg M.J., Leyden W., Horberg M.A., et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007, 167:684-691.
40. Tumbarello M., Rabagliati R., Gaetano Donati K., et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004, 4:46.
41. Cicconi P., Sighinolfi L., Cozzi-Lepri A., et al. Clinical prognosis of HIV-positive patients older than 50 years in the I.C.O.N.A. cohort. Paper presented at: 3rd international AIDS society conference of HIV pathogenesis and treatment 2005, Rio de Janeiro, Brazil, Abstract MoPe11.6C07.
42. Cuzin L., Delpierre C., Gerard S., Massip P., Marchou B. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged>50 years. Clin Infect Dis 2007, 45:654-657.
43. Sabin C.A., Smith C.J., Delpech V., et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med 2009, 10:35-43.
44. Campbell T.B., Smeaton L.M., Kumarasamy N., et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012, 9:e1001290.
45. Spire B., Duran S., Souville M., et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002, 54:1481-1496.